Jeffrey Engelman, MD, PhD

Massachusetts General Hospital, Boston, MA
Lung Cancer Discovery Award

Can We "Teach" Cancer Cells to Die "On Time"?

Jeffrey EngelmanSpecialized treatments called “targeted therapies” are increasingly being used to treat advanced lung cancer. These treatments work by disrupting a process needed for a cancer cell's growth and survival. However, some cancer cells are more resistant to targeted therapies. Dr. Engelman is studying a protein named BIM which regulates programmed cell death. Past studies have found that patients whose cancer had low BIM levels received less benefit from the same targeted therapy as patients whose cancer has high levels of BIM. His research team is trying new ways to cause cell death in the cancers with low BIM. They want to see which patients will have the greatest benefit from targeted therapies, and to find other treatments that may work better against cancers with low BIM in order to improve the response to targeted treatments.

Early detection of lung cancer can increase survival rates. Call the Lung Helpline at 1-800-LUNGUSA or talk to your doctor about lung cancer screening.